Exhibitionistic disorder

ICD-10F65.2	Exhibitionism
DSM-5-TRF65.2	Exhibitionistic Disorder

1. Definition and nosology

Exhibitionistic disorder (ICD-11: 6D30; DSM-5-TR: F65.2) — persistent or intense sexual arousal from exposing genitals to non-consenting persons; the patient experiences significant distress or functional impairment in response to these fantasies, urges, or behaviors, and/or acts on them with actual non-consenting individuals.

2. History

1. Lasègue C. (1877) — term ‘exhibitionnistes’.
2. DSM-III (1980) — Official diagnosis.
3. DSM-5 (2013) — distinction between paraphilia (atypical sexual interest) and paraphilic disorder (clinical distress or harm to others).
4. WFSBP 2020 (Thibaut F. et al.) — international recommendation for paraphilic disorders.

3. Epidemiology

• Prevalence: males 2–4%; rare in females.
• Onset: adolescence and early adulthood.
• Comorbidity: other paraphilia (50–80% of paraphilic disorder patients), ASPD, substance use, MDD.

4. Etiology and pathogenesis

• Numerous factors — biological, behavioral conditioning, psychosocial.
• Comorbid impulsivity and hypersexuality.

5. Clinical features

• Repeated and intense sexual arousal from exposing genitals to non-consenting persons.
• The patient acts on fantasy, impulse, or behavior or experiences distress.
• Typical context — street, public transportation.
• Legal and social consequences (sexual crime).

6. Diagnosis

6.1 Unified diagnostic criteria

A. ≥6 months repeated and intense sexual arousal from genital exposure to non-consenting individuals.

B. The patient has acted on fantasies/impulses or experiences significant distress/functional impairment.

6.2 Differences between sources

• DSM-5-TR requires a 6-month duration; ICD-11 sets no duration criterion — it speaks of a “sustained, focused and intense pattern of arousal”.
• WFSBP 2020 — step-by-step therapy for paraphilic disorders.

6.3 Diagnostic algorithm

• Clinical interview.
• Comorbidity (ASPD, substance, other paraphilic).
• Risk assessment (forensic context).

6.4 Differential diagnosis

7. Examination and assessment

1. Clinical interview.
2. Risk scales (Static-99R for sexual recidivism).

8. Treatment

8.1 General principles (WFSBP 2020 Stepwise)

• CBT (cognitive-behavioral therapy) — first-line; prevention of relapse, management of cognitive distortions.
• SSRIs — high dose (fluoxetine 40–80 mg); reduces impulsivity and sexual drive.
• In refractory cases / severe cases — antiandrogen (CPA cyproterone, MPA medroxyprogesterone).
• In the most severe cases — GnRH agonist (leuprolide, triptorelin) — chemical castration; continuous monitoring.
• Legal-medical coordination.

8.2 Treatment methods

1. CBT (relapse prevention) — Trigger management, cognitive distortion.
2. SSRI High Dose — First pharmacotherapy.
3. Antiandrogen (CPA, MPA) — In refractory cases.
4. GnRH Agonist — In most severe case.

8.3 Differences between sources

1. WFSBP 2020 — step-by-step algorithm.

9. Prognosis

Reduction of relapse with evidence-based treatment; comorbid ASPD and substance use carry a poor prognosis.

10. Myths and misconceptions

Myth 1: “Exhibitionism is harmless”

Evidence: Psychological trauma for the victim; sexual crime; risk of progression to more severe paraphilias.

Myth 2: “Chemical castration is first-line”

Evidence: WFSBP 2020 step‑by‑step — CBT and SSRI first; GnRH in most severe cases.

Myth 3: “Treatment is ineffective”

Evidence: CBT and pharmacotherapy significantly reduce recidivism.

Myth 4: “Only legal punishment is required”

Evidence: Clinical intervention reduces relapse risk.

11. Sources

• WHO. ICD-11. 6D30 Exhibitionistic disorder. 2024.
• APA. DSM-5-TR. 2022.
• Thibaut F., Cosyns P., Fedoroff J.P. et al.; WFSBP Task Force on Paraphilias. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. World J Biol Psychiatry 2020;21(6):412–490.